Valuation: Assembly Biosciences, Inc.

Market Cap 531M 465M 429M 395M 745M 51.15B 762M 5.12B 2.01B 25.01B 2B 1.95B 86.34B P/E 2026 *
-24.7x
P/E 2027 * -9.35x
Enterprise Value 531M 465M 429M 395M 745M 51.15B 762M 5.12B 2.01B 25.01B 2B 1.95B 86.34B EV / Sales 2026 *
11.7x
EV / Sales 2027 * 16.5x
Free-Float
71.58%
Yield 2026 *
-
Yield 2027 * -
1 day+3.75%
1 week-2.15%
Current month-2.44%
1 month+9.70%
3 months-8.31%
6 months-8.72%
Current year-21.17%
1 week 25.36
Extreme 25.36
28.15
1 month 24.01
Extreme 24.01
29.94
Current year 21.8
Extreme 21.795
34.68
1 year 16.9
Extreme 16.9
39.7
3 years 7.69
Extreme 7.692
39.7
5 years 7.69
Extreme 7.692
47.28
10 years 7.69
Extreme 7.692
808.32
Manager TitleAgeSince
Chief Executive Officer 50 31/12/2022
Director of Finance/CFO - 04/06/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 70 03/06/2026
Director/Board Member 61 13/12/2017
Director/Board Member 68 05/08/2019
Date Insider Type Main position Quantity % Market Cap.
17/06/26 Sell

Chief Financial Officer

-29 0.0002%
04/06/26 Free

Director

8,000 0.0514%
04/06/26 Free

Director

8,000 0.0514%
Change 5-day change 1-year change 3-year change Capi.($)
+3.75%-2.15%+43.52%+103.11% 531M
-1.29%-3.11%-0.35%+3.09% 49.18B
+3.90%-0.39%+386.06%+593.85% 39.58B
-1.70%+4.46%+5.93%+60.25% 34.69B
-2.01%-0.76%+28.41%-8.01% 34.42B
+0.06%+0.34%+2.38%+34.38% 27.11B
+0.46%-3.49% - - 16.21B
-0.04%-0.09%+72.42%+115.55% 15.36B
+1.12%+1.91%+14.54%+19.16% 14.05B
0.00%+1.36%+18.43%-30.79% 13.02B
Average +0.42%-0.70%+63.48%+98.95% 24.42B
Weighted average by Cap. -0.05%-0.20%+79.36%+123.27%

Financials

2026 *2027 *
Net sales 45.47M 39.79M 36.75M 33.82M 63.75M 4.38B 65.19M 438M 172M 2.14B 171M 167M 7.39B 32.25M 28.22M 26.07M 23.98M 45.21M 3.1B 46.24M 311M 122M 1.52B 121M 118M 5.24B
Net income -20.46M -17.91M -16.54M -15.22M -28.69M -1.97B -29.34M -197M -77.56M -963M -76.84M -75.15M -3.33B -56.38M -49.33M -45.57M -41.93M -79.04M -5.43B -80.83M -543M -214M -2.65B -212M -207M -9.16B
Net Debt - -
Logo Assembly Biosciences, Inc.
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).
Employees
73
Date Price Change Volume
17/07/26 US$26.81 +3.75% 312,835
16/07/26 US$25.84 -3.33% 309,430
15/07/26 US$26.73 -0.11% 124,814
14/07/26 US$26.76 -0.74% 104,872
13/07/26 US$26.96 -1.61% 112,993
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
26.81USD
Average target price
50.00USD
Spread / Average Target
+86.50%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ASMB Stock